Baraclude Sanctioned for Severe Liver Disease10/18/10
MONDAY, Oct. 18 (HealthDay News) -- Bristol-Myers Squibb said
Monday its liver drug Baraclude (entecavir) has received expanded
approval from the U.S. Food and Drug Administration to treat
chronic hepatitis B in adults with decompensated liver disease, a
form of severe liver damage.
Baraclude was first approved in 2005 for adults with compensated
liver disease, a less severe form of damage that means the liver
still functions properly, the drug maker said in a news
Decompensated liver disease, by contrast, refers to failure of
the liver to maintain adequate function, commonly due to severe
scarring. Chronic hepatitis B often causes chronic liver
inflammation, which can lead to decompensated liver disease, the
drug maker said.
About 1.25 million Americans are infected with chronic hepatitis
B, Bristol said.
The U.S. National Digestive Diseases Information Clearinghouse
has more about
Copyright © 2010
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.